CAMBRIDGE, England & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov 8, 2019--

F-star Therapeutics (“F-star”), a clinical-stage biopharmaceutical company focused on transforming the lives of patients with cancer through the development of innovative tetravalent bispecific (mAb 2™ ) antibodies, today announces that new preclinical data on FS120, a mAb² product candidate targeting OX40 and CD137, will be presented at the Society for Immunotherapy of Cancer (SITC) 2019 Annual Meeting in National Harbor, Maryland, United States, being held from 06 - 10 November 2019.

FS120 is a potentially best-in-class dual agonist that has the potential to overcome cancer resistance by simultaneously engaging OX40 (CD134, TNFRSF4) and CD137 (4-1BB), two receptors found on the surface of tumor-infiltrating lymphocytes. Targeting this class of receptors using bispecific tetravalent binding mobilizes multiple arms of the immune system, which research shows is essential for eliminating tumors. F-star’s preclinical data demonstrated that FS120’s crosslink-dependent approach has the potential to provide therapeutic benefit, for example in combination with checkpoint antagonists, and reverse T cell exhaustion in immunosuppressive tumor environments.

Neil Brewis, CSO of F-star said“Recent clinical trials involving agonist molecules have reported that a meaningful anti-cancer response is often associated with liver toxicity, in line with preclinical observations. F-star’s OX40/CD137 mAb² antibody is showing preclinical evidence that an effective tumor-killing response can be decoupled from liver inflammation. We look forward to progressing FS120 into the clinic as we aim to potentially improve treatment outcomes for patients with difficult-to-treat cancers.”

Some CD137 agonist antibodies have been shown to induce adverse effects either in clinical or in preclinical studies as they constitutively activate T cells and thus release cytotoxic immunity outside of the tumor. In contrast, FS120 is designed to mitigate off-target toxicity through conditional, crosslink-dependent activation upon binding to both OX40 and CD137, which are predominantly present on T cells in the tumor microenvironment.

F-star expects to submit an IND application for FS120 during the fourth quarter of 2019.

Details of the poster are below:

Crosslink-independent CD137 agonism is associated with liver inflammation

Abstract poster number: P775

Poster hall location: Prince George AB

Poster hall hours: 07:00 to 20:00 on Friday 08 November 2019

Poster presentation hours: 12:30 to 14:00 and 18:30 to 20:00 on Friday 08 November 2019

- ENDS -

About F-star

F-star is a clinical-stage immuno-oncology company singularly focused on transforming the lives of patients with cancer through the development of its innovative tetravalent mAb 2 bispecific antibodies. With four distinct binding sites in a natural human antibody format, F-star believes its proprietary approach will overcome many of the challenges facing current immuno-oncology therapies. F-star’s vision is to transform the treatment of cancer through the development of differentiated and well-tolerated mAb 2 bispecific antibodies, which are designed to simultaneously address multiple immune evasion pathways that limit the effect of current immuno-oncology therapies .

mAb 2 ™ is a trademark of F-star.

CONTACT: For investor enquiries

Lindsey Trickett

VP Investor Relations & Communications

+1 240 543 7970

lindsey.trickett@f-star.comConsilium Strategic Communications

Chris Gardner, Sue Stuart, David Daley

Tel: +44 (0)20 3709 5700

E-mail:F-star@consilium-comms.comFor media enquiries

Pierre Peotta

Communications Manager

+44 (0)1223 948 094

+44 (0)7392 080 279

Catherine London, US President

Tel: +1 917-763-2709

E-mail:F-star@consilium-comms.com

KEYWORD: MASSACHUSETTS EUROPE UNITED STATES UNITED KINGDOM NORTH AMERICA

INDUSTRY KEYWORD: BIOTECHNOLOGY HEALTH PHARMACEUTICAL CLINICAL TRIALS ONCOLOGY

SOURCE: F-star

Copyright Business Wire 2019.

PUB: 11/08/2019 07:00 AM/DISC: 11/08/2019 07:01 AM

Copyright Business Wire 2019.